MAFLD group:NA

3 trials

Sponsors

Wuxi Hospital of Traditional Chinese Medicine, Beijing Ditan Hospital, Capital Medical University, First Affiliated Hospital of Kunming Medical University

Conditions

Metabolic-related fatty liver diseaseMetabolically associated fatty liver diseasemetabolic-associated fatty liver disease

Early Phase 1

Characterization of intestinal microbiota in patients with metabolic fatty liver disease (MAFLD) and mechanistic study of its bile acid-FXR axis

Active, not recruitingChiCTR2400089346

Wuxi Hospital of Traditional Chinese MedicineMetabolic-related fatty liver disease

Start: 2022-10-27Updated: 2024-09-09

Unknown Phase

Risk assessment algorithm for carotid plaque in patients with metabolic-associated fatty liver disease

Active, not recruitingChiCTR2500102929

Beijing Ditan Hospital, Capital Medical Universitymetabolic-associated fatty liver disease

Start: 2024-12-01Updated: 2025-05-26

Mechanism by which ACSS2 lactylation regulates the mTOR pathway to influence Th17/Treg cell polarization and mediate the progression of metabolic fatty liver disease

RecruitingChiCTR2600125736

First Affiliated Hospital of Kunming Medical UniversityMetabolically associated fatty liver disease

Start: 2026-05-31Updated: 2026-06-01